Clinical Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
Oncology. 2014;87(1):48-57. doi: 10.1159/000363185. Epub 2014 Jun 25.
Synovial sarcoma is a rare subgroup of all soft-tissue sarcomas. The aim of this retrospective single-center analysis was to investigate the outcome of patients with initially localized disease.
Twenty-six patients were enrolled in this retrospective single-center analysis. Baseline characteristics, treatment and outcome were evaluated.
In 13 patients (50%), the tumor was located in the lower extremity and in 4 patients (15%) in the upper extremity. Surgical resection was done in all but 2 patients (92%). Re-resection was done in 7 patients (27%). Fourteen patients (54%) received adjuvant chemotherapy. After a median follow-up of 23.3 months (range: 2.6-150.3), median disease-free survival was not reached at the time of analysis. Eight patients (31%) relapsed after initial therapy. Surgery was done in 2 patients, amputation in 1 patient, palliative chemotherapy was administered in 3 and radiation therapy in 2 patients. Median overall survival (OS) for all patients was not reached at the time of analysis. The estimated 5-year OS rate was 62%.
Patients with initially localized synovial sarcoma who were included in this retrospective single-center analysis have an estimated 5-year OS rate of 62%.
滑膜肉瘤是所有软组织肉瘤中的一个罕见亚组。本回顾性单中心分析的目的是研究最初局限性疾病患者的预后。
本回顾性单中心分析共纳入 26 名患者。评估了基线特征、治疗和结局。
13 名患者（50%）肿瘤位于下肢，4 名患者（15%）位于上肢。除 2 名患者（92%）外，所有患者均行手术切除。7 名患者（27%）行再次切除术。14 名患者（54%）接受辅助化疗。中位随访 23.3 个月（范围：2.6-150.3）后，分析时无疾病无进展生存的中位时间尚未达到。8 名患者（31%）在初始治疗后复发。2 名患者行手术，1 名患者行截肢，3 名患者行姑息化疗，2 名患者行放疗。分析时所有患者的中位总生存（OS）尚未达到。估计的 5 年 OS 率为 62%。
本回顾性单中心分析纳入的最初局限性滑膜肉瘤患者估计 5 年 OS 率为 62%。
